Maintenance low-dose gemcitabine versus best supportive care in advanced non-small cell lung cancer after first line gemcitabine-cisplatin : Randomized phase III trial
Ahmed Aly Nagy;
Abstract
Lung cancer is the most common cancer in terms of both incidence and mortality worldwide.
The majority of patients with non-small-cell lung cancer (NSCLC) have advanced disease (stage IIIB or IV). Several randomized studies have demonstrated an advantage
The majority of patients with non-small-cell lung cancer (NSCLC) have advanced disease (stage IIIB or IV). Several randomized studies have demonstrated an advantage
Other data
| Title | Maintenance low-dose gemcitabine versus best supportive care in advanced non-small cell lung cancer after first line gemcitabine-cisplatin : Randomized phase III trial | Other Titles | المكونة من الخلايا غير الصغيرة بالمراحل المتقدمة بعد خط العلاج الأول المكون من عقارى الجمسيتابين و السيسبلاتين | Authors | Ahmed Aly Nagy | Keywords | Maintenance low-dose gemcitabine versus best supportive care in advanced non-small cell lung cancer after first line gemcitabine-cisplatin : Randomized phase III trial | Issue Date | 2013 | Description | Lung cancer is the most common cancer in terms of both incidence and mortality worldwide. The majority of patients with non-small-cell lung cancer (NSCLC) have advanced disease (stage IIIB or IV). Several randomized studies have demonstrated an advantage |
Attached Files
| File | Size | Format | |
|---|---|---|---|
| 114674a5211.pdf | 297.72 kB | Adobe PDF | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.